公开(公告)号：WO0035408A3

公开(公告)日：2000-11-02

申请号：PCT/US9930101

申请日：1999-12-16

Applicant: PATHOGENESIS CORP

Inventor： ROSE LYNN M ,  PORUBEK DAVID J ,  MONTGOMERY ALAN B

IPC: C07D498/18 ,  A61K9/02 ,  A61K9/14 ,  A61K9/20 ,  A61K9/50 ,  A61K9/52 ,  A61K31/00 ,  A61K31/133 ,  A61K31/42 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/70 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7052 ,  A61K38/00 ,  A61P1/04 ,  A61P11/00 ,  A61P31/04 ,  A61P31/06 ,  A61P31/18 ,  A01N43/40 ,  A61K31/44

CPC classification number: A61K31/538 ,  A61K31/00 ,  A61K31/70 ,  C10M101/025 ,  C10M103/06 ,  C10M105/14 ,  C10M105/24 ,  C10M107/34 ,  C10M107/36 ,  C10M111/00 ,  C10M2201/0603 ,  C10M2201/0613 ,  C10M2201/0623 ,  C10M2201/0653 ,  C10M2201/0663 ,  C10M2201/0803 ,  C10M2201/0853 ,  C10M2201/0863 ,  C10M2201/0873 ,  C10M2201/1006 ,  C10M2201/1023 ,  C10M2201/1033 ,  C10M2201/1053 ,  C10M2201/123 ,  C10M2205/143 ,  C10M2205/163 ,  C10M2205/173 ,  C10M2205/183 ,  C10M2207/0225 ,  C10M2207/1203 ,  C10M2207/1213 ,  C10M2207/1253 ,  C10M2207/163 ,  C10M2207/183 ,  C10M2207/203 ,  C10M2207/243 ,  C10M2209/1033 ,  C10M2209/1045 ,  C10M2209/1055 ,  C10M2209/1065 ,  C10M2209/1075 ,  C10M2209/1085 ,  C10M2209/1095 ,  C10M2209/123 ,  Y10S514/924 ,  Y10S514/931 ,  A61K2300/00

Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

Abstract translation: 利福拉齐治疗细菌感染的方法，每周一次或每周两次。 一种治疗由结核分枝杆菌引起的肺结核，由鸟分枝杆菌复合物引起的感染，由肺炎衣原体引起的感染和由幽门螺杆菌引起的感染的方法，通过给患有细菌感染的患者施用1-100mg利福拉齐每周一次或两次 。 在该剂量方案中，治疗速度快，有效且消除了每日剂量1-50mg利福拉齐所观察到的不良继发症状。

公开(公告)号：AU2710600A

公开(公告)日：2000-07-03

申请号：AU2710600

申请日：1999-12-16

Applicant: PATHOGENESIS CORP

Inventor： ROSE LYNN M ,  PORUBEK DAVID J ,  MONTGOMERY ALAN B

IPC: C07D498/18 ,  A61K9/02 ,  A61K9/14 ,  A61K9/20 ,  A61K9/50 ,  A61K9/52 ,  A61K31/00 ,  A61K31/133 ,  A61K31/42 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/70 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7052 ,  A61K38/00 ,  A61P1/04 ,  A61P11/00 ,  A61P31/04 ,  A61P31/06 ,  A61P31/18

Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly, or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

公开(公告)号：CA2355283A1

公开(公告)日：2000-06-22

申请号：CA2355283

申请日：1999-12-16

Applicant: PATHOGENESIS CORP

Inventor： ROSE LYNN M ,  PORUBEK DAVID J ,  MONTGOMERY ALAN B

IPC: C07D498/18 ,  A61K9/02 ,  A61K9/14 ,  A61K9/20 ,  A61K9/50 ,  A61K9/52 ,  A61K31/00 ,  A61K31/133 ,  A61K31/42 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/70 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7052 ,  A61K38/00 ,  A61P1/04 ,  A61P11/00 ,  A61P31/04 ,  A61P31/06 ,  A61P31/18 ,  A01N43/40 ,  A61K31/44

Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused b y Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex , infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacteri al infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

公开(公告)号：CA2355283C

公开(公告)日：2009-02-17

申请号：CA2355283

申请日：1999-12-16

Applicant: PATHOGENESIS CORP

Inventor： MONTGOMERY ALAN B ,  PORUBEK DAVID J ,  ROSE LYNN M

IPC: A61K31/5383 ,  C07D498/18 ,  A61K9/02 ,  A61K9/14 ,  A61K9/20 ,  A61K9/50 ,  A61K9/52 ,  A61K31/00 ,  A61K31/133 ,  A61K31/42 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/538 ,  A61K31/70 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7052 ,  A61K38/00 ,  A61P1/04 ,  A61P11/00 ,  A61P31/04 ,  A61P31/06 ,  A61P31/18

Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.